60 Degrees Pharmaceuticals, Inc. (SXTP) is a specialty pharmaceutical company developing and commercializing medicines for infectious and vector-borne diseases, led by its FDA-approved malaria prevention therapy ARAKODA (tafenoquine). The micro-cap stock trades near $0.94, and the central price objective examined here is $3.70 — a level that would require a move of roughly 294%, a very large advance for any security. This analysis weighs the evidence for and against that objective without making a prediction.
SXTP has minimal sell-side coverage, and the price-target picture is complicated by a 1-for-4 reverse stock split completed in January 2026 to regain Nasdaq's minimum bid price requirement. After the split, H.C. Wainwright raised its target to $24 in late January 2026, but the firm downgraded the stock to Neutral in May 2026, effectively removing that aggressive objective. The only current, verifiable analyst price target is $3.70 from Ascendiant Capital (analyst Lucas Ward), maintained with a Buy rating in May 2026 after being lowered from $4.20.
Because only one current target remains, $3.70 is best understood as a single firm's objective and the realistic price level most discussed publicly — not an official analyst consensus. Aggregator figures that still cite higher averages reflect stale, pre-downgrade targets and should not be treated as a current consensus. Investors should weigh the $3.70 objective against the broader fundamental picture rather than relying on one analyst's number.
SXTP trades near $0.94, close to the lower end of its 52-week range of roughly $0.90 to $8.62 on a split-adjusted basis. Reaching $3.70 would require an increase of about 294%, which qualifies as a very large move. The stock has been volatile since the reverse split, rallying in early 2026 on positive babesiosis data before giving back much of those gains.
The company remains unprofitable. For the most recent full fiscal year, revenue was roughly $1 million, and the company continues to post negative EPS (earnings per share), with analyst estimates projecting continued losses. Any sustained move toward $3.70 would likely depend on a step-change in the clinical and commercial narrative rather than modest operational progress.
On a split-adjusted basis, SXTP's 52-week range spans roughly $0.90 to $8.62, and the stock sits near the bottom of that range. The area around $0.90 has acted as a meaningful support level, while $1.00 represents an immediate psychological resistance level. A move toward $3.70 would require clearing multiple overhead levels, including the prior consolidation zones in the low-single-digits that formed after the 2026 rally. The long-term trend structure remains firmly in a downtrend after the stock retraced most of its post-split gains.
Analyst price targets typically reflect a research horizon of roughly 12 months, though the specific horizon for the $3.70 objective was not disclosed. Investors should monitor quarterly earnings and cash runway updates, the babesiosis study's enrollment and top-line data, any new financing or dilution, Nasdaq compliance status, and further analyst rating or target changes. Given the stock's volatility, even company news can produce sharp, unpredictable swings.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like SXTP, such tools can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual review. Explore the platform to see how these signals can support your own market research and decision-making process.
The $3.70 objective for 60 Degrees Pharmaceuticals reflects a single current analyst target and widely discussed public price level, not a broad consensus. Reaching it would require a very large gain of roughly 294% from the recent price near $0.94. The strongest supports are the tafenoquine babesiosis data and a diversified pipeline, while persistent losses, financing needs, thin revenue, and a recent analyst downgrade are the principal obstacles. With minimal coverage and high volatility, the outcome will likely hinge on upcoming clinical data and the company's ability to fund operations without excessive dilution. No outcome is guaranteed, and this analysis makes no prediction or investment recommendation.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that SXTP and OCGN have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SXTP and OCGN's prices will move in lockstep.
| Ticker / NAME | Correlation To SXTP | 1D Price Change % | ||
|---|---|---|---|---|
| SXTP | 100% | -0.79% | ||
| OCGN - SXTP | 31% Poorly correlated | +0.32% | ||
| ACXP - SXTP | 30% Poorly correlated | +0.88% | ||
| MLYS - SXTP | 29% Poorly correlated | -2.22% | ||
| CRSP - SXTP | 27% Poorly correlated | +1.24% | ||
| DNLI - SXTP | 26% Poorly correlated | -1.32% | ||
More | ||||